In this article we will discuss Durvalumab (Patient Counseling-1). So, let’s get started. One has to inform patients the risk of immune-mediated adverse reactions with Durvalumab that may require corticosteroid treatment and interruption or discontinuation of Durvalumab. • Pneumonitis: Advise patients to contact their healthcare provider immediately for any new or worsening cough, chest pain, […]
Category: Durvalumab
In this article we will discuss Durvalumab (Storage). So, let’s get started. Durvalumab Injection is a clear to opalescent, colorless to slightly yellow solution supplied in a carton containing one single-dose vial either as: • 500 mg/10 mL (NDC 0310-4611-50) • 120 mg/2.4 mL (NDC 0310-4500-12) Store in a refrigerator at 2°C to 8°C (36°F […]
In this article we will discuss Durvalumab (Clinical Studies-12)
In this article we will discuss Durvalumab (Clinical Studies-11)
In this article we will discuss Durvalumab (Clinical Studies-10)
In this article, we will discuss Durvalumab (Clinical Studies-9). So, let’s get started. The major efficacy outcome measures were progression-free survival (PFS) as assessed by a BICR v1.1, and overall survival (OS). Additional efficacy outcome measures included ORR and DoR assessed by BICR.